Refractory Lymphomas Not Yet Recruiting Phase 2 Trials for Rituximab (DB00073)

Also known as: Refractory Lymphoma

IndicationStatusPhase
DBCOND0042145 (Refractory Lymphomas)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03418038Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory LymphomaTreatment